Jayne Danska

External Scientific Advisory Committee (ESAC) External Scientific Advisory Committee (ESAC), co-chair
  • Senior Scientist, Program in Genetics and Genome Biology and,
  • Associate Chief, Faculty Development and Diversity, Hospital for Sick Children Research Institute
  • Anne and Max Tanenbaum Chair in Molecular Medicine, and
  • Professor, Department of Immunology and Department of Medical Biophysics, University of Toronto

Dr. Danska was raised in New York City, and educated in the United States at Kenyon College, Cornell University, Cold Spring Harbor Labs and Stanford University. Her research is focused on defining the mechanisms underlying immune system diseases and application of this knowledge to improve their diagnosis, prevention and treatment. Her lab works on the genetic and environmental causes of autoimmune disease, particularly Type 1 diabetes (T1D), the molecular mechanisms of acute lymphoid leukemia (ALL), and innate immune surveillance of leukemia and leukemia stem cells.  
 
She has led multi-disciplinary projects applying genetic, genomic and immunological analysis to identify T1D-risk genes and to determine how these variants control autoimmune pathogenesis. An evolving focus is the roles of environmental factors in the rising rates of autoimmune and inflammatory diseases, specifically the role of the intestinal microbiome in modifying inherited risk of autoimmunity in rodent models and in longitudinal studies in children with high genetic risk for type 1 and type 2 diabetes. This work is also investigating the impact of sex as a key determinant of autoimmune diseases, many of which are far more prevalent in females. 

Research

Dr. Danska’s research is focused on defining the mechanisms underlying immune system diseases and application of this knowledge to improve their diagnosis, prevention and treatment. Her lab works on the genetic and environmental causes of autoimmune disease, particularly Type 1 diabetes (T1D), the molecular mechanisms of acute lymphoid leukemia (ALL), and innate immune surveillance of leukemia and leukemia stem cells. 

She has led multi-disciplinary projects applying genetic, genomic and immunological analysis to identify T1D-risk genes and to determine how these variants control autoimmune pathogenesis. An evolving focus is the roles of environmental factors in the rising rates of autoimmune and inflammatory diseases, specifically the role of the intestinal microbiome in modifying inherited risk of autoimmunity in rodent models and in longitudinal studies in children with high genetic risk for type 1 and type 2 diabetes. This work is also investigating the impact of sex as a key determinant of autoimmune diseases, many of which are far more prevalent in females.

In addition, Dr. Danska and her collaborators discovered a signaling pathway in macrophages pivotal to the survival of human normal hematopoietic stem cells and acute leukemia stem cells that sustain leukemic growth. They have developed a biologic therapy to manipulate this immune checkpoint to impair the survival of leukemia and other blood cell cancers that is now in clinical trials.